Delcath Systems Inc (DCTH)

Currency in USD
10.650
+0.290(+2.80%)
Closed·
10.830+0.180(+1.69%)
·
DCTH Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
DCTH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
10.30010.810
52 wk Range
7.54018.230
Key Statistics
Prev. Close
10.36
Open
10.3
Day's Range
10.3-10.81
52 wk Range
7.54-18.23
Volume
574.09K
Average Volume (3m)
768.96K
1-Year Change
38.13%
Book Value / Share
3.09
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DCTH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
24.333
Upside
+128.48%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Delcath Systems Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Delcath Systems Inc Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York.

Delcath Systems Inc Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of $0.07, beating $0.03 forecast; revenue of $24.2M surpassed $22.78M expectation; stock up 17.87% pre-market
  • Net income of $2.7M, reversing $13.7M loss from previous year; revenue up 20% YoY; gross margin improved to 86% from 80%
  • Full-year revenue guidance of $93M-$96M; projected 175% increase in Hepcidol treatment volume compared to 2024
  • CEO emphasized strategic focus on scaling and targeting world-class cancer centers; expansion of treatment sites and sales force noted
  • Analysts inquired about National Drug Rebate Agreement participation, 340B program, and challenges in site activation
Last Updated: 06/08/2025, 14:56
Read Full Transcript

Compare DCTH to Peers and Sector

Metrics to compare
DCTH
Peers
Sector
Relationship
P/E Ratio
166.9x−4.1x−0.6x
PEG Ratio
1.59−0.150.00
Price/Book
3.5x3.1x2.6x
Price / LTM Sales
5.3x2.8x3.3x
Upside (Analyst Target)
126.8%41.4%40.2%
Fair Value Upside
Unlock14.5%5.1%Unlock

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 24.333
(+128.48% Upside)

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
0.07 / 0.03
Revenue / Forecast
24.20M / 22.78M
EPS Revisions
Last 90 days

DCTH Income Statement

People Also Watch

16.66
OSCR
+6.49%
19.710
ZETA
+3.03%
54.87
BMNR
-5.09%
186.43
ALAB
+0.31%
6.3300
EOSE
+8.02%

FAQ

What Stock Exchange Does Delcath Systems Trade On?

Delcath Systems is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Delcath Systems?

The stock symbol for Delcath Systems is "DCTH."

What Is the Delcath Systems Market Cap?

As of today, Delcath Systems market cap is 372.20M.

What Is Delcath Systems's Earnings Per Share (TTM)?

The Delcath Systems EPS (TTM) is 0.07.

When Is the Next Delcath Systems Earnings Date?

Delcath Systems will release its next earnings report on 10 Nov 2025.

From a Technical Analysis Perspective, Is DCTH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Delcath Systems Stock Split?

Delcath Systems has split 5 times.

How Many Employees Does Delcath Systems Have?

Delcath Systems has 96 employees.

What is the current trading status of Delcath Systems (DCTH)?

As of 18 Aug 2025, Delcath Systems (DCTH) is trading at a price of 10.65, with a previous close of 10.36. The stock has fluctuated within a day range of 10.30 to 10.81, while its 52-week range spans from 7.54 to 18.23.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.